Carbon monoxide (CO) is a toxic gas and common air pollutant in human environments. Research into the health effects of CO has historically focused on acute, high-dose exposure, yet evidence points to health effects of low-dose CO, especially in the brain, where it has been associated with neurodegenerative diseases, such as Parkinson’s. Furthermore, low-dose CO has mostly been studied in isolation, yet exposure often occurs alongside other air pollutants, such as fine particulate matter (PM2.5). Many of these pollutants, including PM2.5, also show effects in the brain and have been linked to neurodegenerative diseases. Therefore, combined exposure may modulate the effects of low-dose CO, leading to poorer health outcomes. Despite commonly co-occurring in human environments, the neurodegenerative effects of combined low-dose CO and PM2.5 exposure are unknown. This project aims to answer this question by characterising the toxicity and related mechanisms of low-dose CO and PM2.5 exposure in Parkinson’s.
To study effects relating to Parkinson’s, this project will expose and study dopamine-producing brain cells, the primary cells affected in Parkinson’s. These cells will be grown in the lab, a technique widely used in Parkinson’s research to accurately model the biology of patients, supporting the translation of results from the lab and into patients. To determine interactions between low-dose CO and PM2.5 exposure, the two will be studied individually and combined at a range of doses. Initial exposures will be performed for 24 hours at 0 – 200 ppm CO and 0 – 100 µg/ml PM2.5, based on results from previous studies.
To determine the toxicity of low-dose CO and PM2.5 to dopamine-producing brain cells, we will measure the survival of cells during and following exposure. This data will provide evidence on the direct link between exposures and Parkinson’s, as death of these cells is the primary event in Parkinson’s progression. To determine the activation of classical neurodegeneration mechanisms by low-dose CO and PM2.5, we will measure oxidative stress and mitochondrial dysfunction during and following exposure. This data will provide mechanistic understanding of CO and PM2.5 exposure in dopamine-producing brain cells, bringing much-needed clarity to their role in Parkinson’s. While this study will be carried out in dopamine-producing brain cells, similarity between many types of brain cells makes this data applicable across the wider brain and other neurological diseases. Therefore, the data from this project will help us to define the doses of CO and PM2.5, individually and combined, that are toxic to the brain.
Using a novel dual exposure approach, more representative of real-world exposures, this project will provide translatable understanding on the human health risks posed by low-dose CO. This research will also provide insight into the risks posed by different CO sources, each of which have unique pollutant signatures.
Altogether, this will support improved targeting of awareness and prevention campaigns; inform policymakers on the safety of CO and its sources; and provide potential routes for the development of therapeutics.